Submit Manuscript  

Article Details

Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors

[ Vol. 19 , Issue. 4 ]


Dmitry I. Osolodkin, Vladimir A. Palyulin and Nikolay S. Zefirov   Pages 665 - 679 ( 15 )


Glycogen synthase kinase 3 (GSK-3) is a ubiquitous serine/threonine protein kinase participating in numerous pathways. Very important among them are cancer-related pathways, such as Wnt pathway and nuclear factor κB pathway. The recent findings concerning possible applicability of GSK-3 inhibitors as anticancer agents are summarized in this review, and controversies in the data are highlighted. The most actual concepts of GSK-3 inhibitor design are also thoroughly discussed.


Glycogen synthase kinase 3, molecular design, cancer treatment, kinase inhibitors, Wnt pathway


Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory 1/3, Moscow 119991 Russia.

Read Full-Text article